Trial Profile
Compassionate study to evaluate the efficacy of Brentuximab Vedotin in patients with relapsed or refractory peripheral T-Cell lymphoma.
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications T-cell lymphoma
- Focus Expanded access; Therapeutic Use
- 19 Dec 2015 New trial record